TED may result in changes across the entire face

A study found that the effects thyroid eye disease (TED) has on soft tissue may expand beyond the orbit and periorbita, resulting in changes across the entire face.

The data presented at ASOPRS 52nd Annual Fall Scientific Symposium showed that amongst 43 patients with TED, a reduction in volume for the upper face (0.74 mL), the periorbital region (1.8 mL), the temples (0.18 mL), the midface (1.73 mL), and the lower face (2.84 mL) was achieved after treatment with teprotumumab. The volume of the full face decreased by a mean of 8.4 mL.

There was also a significant reduction in Margin-to-reflex distance 1 and 2, as well as the intercanthal distance following treatment (P < 0.05).

Prior to the start of the study, no participants had plans to lose weight or begin medication that may result in weight loss. The mean starting weight was 75 kg. After therapy mean weight was 69 kg. No relationship was found between prior steroid use and reduction in total body weight or changes in facial volume.

Reference
Ugradar S, et al. Reversal of Graves’ Disease-Associated Facial Volume Expansion and Eyelid Changes Following Teprotumumab Therapy. Presented at: ASOPRS 52nd Annual Fall Scientific Symposium.